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Abstract Tourette syndrome (TS) is a neuropsychiatric
disorder characterized by recurrent motor and vocal tics,
often accompanied by obsessive–compulsive disorder and/
or attention-deficit/hyperactivity disorder. While the evi-
dence for a genetic contribution is strong, its exact nature
has yet to be clarified fully. There is now mounting evi-
dence that the genetic risks for TS include both common
and rare variants and may involve complex multigenic
inheritance or, in rare cases, a single major gene. Based on
recent progress in many other common disorders with
apparently similar genetic architectures, it is clear that
large patient cohorts and open-access repositories will be
essential to further advance the field. To that end, the large
multicenter Tourette International Collaborative Genetics
(TIC Genetics) study was established. The goal of the TIC
Genetics study is to undertake a comprehensive gene
discovery effort, focusing both on familial genetic variants
with large effects within multiply affected pedigrees and on
de novo mutations ascertained through the analysis of
apparently simplex parent–child trios with non-familial
tics. The clinical data and biomaterials (DNA, transformed
cell lines, RNA) are part of a sharing repository located
within the National Institute for Mental Health Center for
Collaborative Genomics Research on Mental Disorders,
USA, and will be made available to the broad scientific
community. This resource will ultimately facilitate better
understanding of the pathophysiology of TS and related
disorders and the development of novel therapies. Here, we
describe the objectives and methods of the TIC Genetics
study as a reference for future studies from our group and
to facilitate collaboration between genetics consortia in the
field of TS.
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Introduction
Tourette syndrome (TS) is a neuropsychiatric develop-
mental disorder characterized by rapid, recurrent, non-
rhythmic movements (motor tics) and vocalizations (vocal
tics) [1]. TS is etiologically closely linked to other chronic
tic disorders, such as chronic motor or vocal tic disorder.
The worldwide prevalence of TS is estimated to be
between 0.3 and 1 % and onset is typically in early
childhood [2, 3]. Many children and adults with TS also
meet criteria for comorbid obsessive–compulsive disorder
(OCD, 30–50 %) [4], attention-deficit/hyperactivity disor-
der (ADHD, about 40–60 %) [3, 5, 6], or other comor-
bidities [7]. Although both drug and behavior therapies can
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often at least partially alleviate tic and comorbid symptoms
and improve quality of life [8–10], current medications
frequently have unwanted side effects and a substantial
number of patients do not show positive or only limited
responses to either drug and/or behavioral interventions [8–
12]. Although the majority of young patients experience a
spontaneous improvement of tic severity by young adult-
hood [6], about 25 % of patients with TS continue to have
moderate to severe tic symptoms into adulthood [4, 6] and
many individuals continue to suffer from the negative
social consequences, even after the tics have subsided [12–
14]. At present, there are insufficient data to guide the
development of specifically targeted therapies. Thus, there
is a pressing need for a better understanding of the path-
ophysiology of TS and related disorders to develop novel
treatments that target the underlying cause(s).
While family and twin studies have consistently pointed
to a significant genetic contribution, the molecular basis of
TS is not well understood and progress in gene discovery
has been slow relative to other neuropsychiatric disorders
[15]. Since early segregation studies had suggested single-
gene autosomal dominant transmission in TS [16–18], first
gene discovery efforts were directed at very large pedi-
grees. These early investigations focused either on tradi-
tional linkage analysis or mapping of chromosomal
abnormalities [19, 20]. However, later segregation studies
have suggested a more complex inheritance pattern
involving multiple genes (for a review, see [21]) and the
model of a uniform single dominant gene no longer holds.
Moreover, environmental factors (such as pre- and peri-
natal events), gene9environment interactions, and likely
genetic heterogeneity add to the complexity of unraveling
the etiology of TS [22, 23].
Although various genes and chromosomal regions have
been implicated in TS etiology, to date, no single risk gene
or genetic variation has been definitively established as a
uniform cause or contributing factor for TS (for a review,
see [21, 23]). The growing appreciation of the involvement
of multiple genetic variants in TS fuelled the application of
large genome-wide association study (GWAS) designs.
While the study of common variants based on a case–
control design in very large samples appears promising, in
the only large GWAS study published to date, no locus
reached the threshold for genome-wide significance [24].
Meanwhile, the burgeoning development of genomic
technologies, including micro-arrays and next-generation
sequencing, has fostered renewed interest in studying
multiply affected family pedigrees to search for rare vari-
ants of large effects, variants that would not be captured in
GWAS studies, which focus on common single-nucleotide
polymorphisms (SNPs) of small effects [15, 25, 26]. Micro-
arrays have also been used for studying de novo copy
number variations (CNVs) by using parent–child trios;
identifying de novo mutations possibly underlying TS can
be enhanced by investigating non-familial forms of TS
through the analysis of apparently simplex trios (i.e., an
affected individual with both parents unaffected) [15, 21,
25, 26]. The studies of rare variants have yielded intriguing
findings that implicate genes involved in histaminergic and
serotonergic pathways ([27–29], see also [30]) and genes
involved in promoting dendritic growth [20, 31].
To summarize, it is now recognized that TS is almost
certainly the result of complex and heterogeneous inheri-
tance involving both common and rare variants [21], which
are likely interacting with environmental factors [22, 23].
Based on the rapid progress in other neurodevelopmental
disorders such as autism and schizophrenia [32], it has
become clear that large patient cohorts are essential for gene
discovery efforts [15]. Large open-access repositories that
include well-characterized probands and family pedigrees
will promote innovative studies utilizing emerging tech-
nologies to understand the genetic architecture of complex
diseases, including TS and related disorders [21, 23].
The TIC Genetics study
The Tourette International Collaborative Genetics (TIC
Genetics; http://tic-genetics.org) study was established in
2011 to further our understanding of the genetic architec-
ture of tic disorders by developing a large sample of
genotypically and phenotypically well-characterized
affected probands and relatives. The study employs state-
of-the-art genetic technologies to identify major genetic
variants contributing to TS and the most commonly
comorbid disorders, including OCD and ADHD. Specifi-
cally, TIC Genetics searches for likely deleterious muta-
tions that are shared by affected individuals within multiply
affected families. A second focus is searching for de novo
mutations, particularly rare loss of function variants that
occur in the same gene in more than one individual.
Identifying de novo mutations is an especially promising
gene-finding approach, given the expected higher signal-to-
noise ratio when comparing the affected child versus
unaffected parents, using CNV, whole-exome and whole-
genome analysis [33]. We also aim to explore interactions
between susceptibility genes and perinatal environmental
factors with regard to the clinical phenotype and will
investigate genome-wide gene expression of peripheral
blood mRNA from TS probands carrying selected CNVs of
interest or segregating rare mutations. We will evaluate the
contribution of the entire allelic spectrum to TS.
The TIC Genetics study is an international collaboration
of more than twenty sites from the USA, Europe, and South
Korea, including academic research centers and mental
health care settings led by experienced clinicians and
investigators in TS and related disorders. The study sites
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Table 1 Overview of measures. Clinical assessments and diagnoses are based on self- or parent-on-child reports and a subsequent clinical
interview in accordance with Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV-TR criteria [35]
Topics Measures Measurement instruments, examples of variables
Demographic information and health
indicators
Tourette Syndrome Association Genetic Linkage
Consortium’s Family Self-Report Questionnaire
(TSA, January 1995; http://www.findTSgenes.
org)
Demographics Race, ethnicity, schooling, parent education/
occupation, birth order, handedness, etc.
Subject’s medical history Range of pulmonary, dermatologic, allergic,
cardiovascular diseases, neurological conditions,
congenital anomalies, genetic syndromes, etc.
Psychotropic medication use (lifetime and
past two weeks)
Broad range of neuroleptics, selective serotonin
reuptake inhibitors, other antidepressants, mood
stabilizers, benzodiazepines, stimulants etc.
Family history of tic and other relevant
psychiatric and medical disorders
OCD, ADHD, hair pulling, autism spectrum
disorders, mental retardation, neurological
disorders, genetic syndromes, etc., of family
members
Psychopathological disorders and
symptoms, lifetime and past week
Tic disorders Tourette syndrome Yale Global Tic Severity Scale (YGTSS, Leckman
et al. [36])Chronic tic disorders (chronic motor or
vocal tic disorder, or combined subtypea)
Transient tic disorder
Provisional tic disorder (DSM-5 [47])
Tic disorder-NOS
Obsessive–compulsive disorder
(OCD) or OC symptoms
OCD
Subclinical OCD
OC symptoms
Yale–Brown Obsessive–Compulsive Scale
(Y-BOCS, Goodman et al. [38, 39])
Trichotillomania Questions on past and present hair pulling, pulling
eye-lashes or eyebrows resulting in noticeable
hair loss
Attention-deficit/hyperactivity
disorder (ADHD)
Combined type
Predominantly inattentive type
Predominantly hyperactive–impulsive type
Subclinical ADHD
Swanson Nolan and Pelham-IV (SNAP-IV,
Swanson et al. 1992) [43]
Other medical or psychiatric history,
or aggressive episodes
Neurological, medical, or genetic disorders; autism
spectrum disorders, psychotic disorders, anxiety
disorders, mood disorders, externalizing
disorders, etc., by clinician review
Environmental risk factors Prenatal, perinatal, and developmental
history
Pregnancy, Birth, and Development Questionnaire
(Modified schedule for risk and protective factors
early in development; Walkup and Leckman [51,
52])
Pregnancy (maternal age, paternal age, pregnancy
duration, special medical procedures or problems
during pregnancy, medication use, use of
substances [smoking, alcohol, street drugs,
caffeine])
Labor and delivery (birth weight, gestational age,
complications, multiple pregnancy, medications,
premature birth)
Newborn period (APGAR scores, medical
concerns, problems, and interventions)
First years of life (developmental milestones)
Biomaterials DNA, transformed cell lines, RNA
a Separate category not covered in the DSM for individuals with a history of only a single motor tic and at least one vocal tic, with onset by age 18 years
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recruit and clinically assess individuals with TS and their
family members, and collect blood samples for DNA and
RNA extraction. The clinical and biomaterial data are part
of a sharing repository of the National Institute for Mental
Health (NIMH) Center for Collaborative Genomics
Research on Mental Disorders in the USA and will be
made available to the research community at large to
hasten the identification of causal genetic factors and
facilitate better understanding and treatment of this often
impairing disorder. The repository includes DNA, trans-
formed cell lines, and RNA. Hereafter, we describe the
methods of the TIC Genetics study and how to gain access
to the repository.
Methods
Subjects
Recruitment started in September 2011 and is ongoing. The
TIC Genetics study’s current aim is to ascertain at least
1,548 subjects from multiplex families (affected family
pedigrees) or parent–child trios (a trio includes an affected
proband with both biological parents). Probands must meet
criteria for TS or another chronic tic disorder (see Table 1
for definitions). Multiplex families consist of an affected
proband with a tic disorder and at least two other relatives
(up to the fourth degree) with a tic disorder or OCD (at
least one of the relatives must have a tic disorder, others
may also have OCD). In those families, unaffected first-
degree relatives of affected participants are also recruited,
as well as connecting relatives (e.g., grandparents of first
cousins). Enrollment of bilineal pedigrees (i.e., tics in both
paternal and maternal sides) is permitted, but discouraged
as they are less informative [34]. Apart from multiplex
families, we focus on recruiting simplex trios in which only
the proband but neither parent nor siblings (and preferably
no other known family member) has a tic disorder.
Subjects are not excluded based on age, gender, race, or
ethnicity. Exclusion criteria are limited to inability to
obtain appropriate informed consent, refusal of blood
sampling by minors, or situations in which, in the physi-
cian’s best judgment, it would not be in the subject’s best
interest to be enrolled.
Subjects are recruited from all collaborating sites based
on new referrals, previously diagnosed tic disorder patients,
and occasionally via patient organizations. Each clinical
recruiting center has obtained separate study approval from
their local Human Investigations Committee. Adults, as
well as the child’s biological parent(s) (or legal guardian) in
case of minors, provide written informed consent and the
participating child gives written or oral assent before
entering the study. The informed consent specifies inclusion
into a sharing repository through the NIMH Center for
Collaborative Genomics Research on Mental Disorders,
USA (www.nimhgenetics.org) as a requirement. All par-
ticipating subjects give consent for submission of anony-
mized data to, and distribution from, an NIMH repository.
Data collection procedure
All collaborating centers follow the same standardized data
collection procedures (Fig. 1). Consenting probands and
their family members are invited for a single visit to the
respective centers, providing a set of completed standardized
and well-validated tic, OCD, and ADHD rating instruments
(adult self-report and/or parent-on-child report). Experi-
enced clinicians specialized in TS review the instruments
during an in-person semi-structured clinical interview of all
participants regarding the presence or absence of lifetime
and current tic and other neuropsychiatric disorders and
assign clinical diagnoses. After the evaluation, the coded de-
identified demographic data and clinical diagnoses are
entered into our online password-protected data-entry sys-
tem. Here, the clinician rates each diagnostic criterion for tic
disorder, OCD, and ADHD and the corresponding disorder
as ‘‘present’’, ‘‘absent’’, or ‘‘unable to rate’’ based on the
Diagnostic and Statistical Manual of Mental Disorders—
Fourth edition, Text Revision (DSM-IV-TR) [35]. The
online system utilizes internal algorithms to ensure complete
data entry and the appropriate match between the reported
diagnostic criterial symptoms and the assigned correspond-
ing diagnoses for each of these disorders. The evaluating
clinician also provides a short diagnostic narrative report for
each subject. Scans of the completed de-identified ques-
tionnaires are sent to the data coordination center at Rutgers
University. Finally, blood of participants (total of 30 ml) is
collected by a single venipuncture and immediately shipped
to the NIMH Center for Collaborative Genomics Research
on Mental Disorders at RUCDR (RUCDR Infinite Biologics,
http://www.rucdr.org) at Rutgers University, Piscataway,
NJ, USA.
Clinical assessments
Adult self-report and parent-on-child report questionnaires
followed by clinician review
Table 1 shows an overview of the clinical assessment
measures. Adult self-reports and parallel parent-on-child
report questionnaires are used to assess subjects’ demo-
graphics, medical history, psychopathology, and selected
environmental factors, as well as family members’ psy-
chiatric history.
Lifetime and current (i.e., past week) tic, obsessive–
compulsive, trichotillomania (a condition, sometimes
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associated with TS), and ADHD symptoms corresponding
to DSM-IV-TR [35] criteria are initially assessed by adult
self- and parallel parent-on-child ratings which are
reviewed during a follow-up clinical interview by board-
certified clinicians who are experienced in the evaluation
and treatment of TS and who assign the clinical diagnoses
based on that review. Included are the widely used, highly
reliable and well-validated Yale Global Tic Severity Scale
(YGTSS) [36, 37] and Yale–Brown Obsessive–Compul-
sive Scale (Y-BOCS) [38–40]. While the latter were orig-
inally developed as semi-structured interviews, self-report
and parent-on-child questionnaires for each have been
developed and used (see in [41, 42]). TIC Genetics uses
modified versions of these self- or parent-on-child reports
to provide a standardized initial symptom inventory, fol-
lowed by clinician review and validation of symptom
reports (see [41] and [42] for a comparable procedure). The
original YGTSS contains a tic section consisting of an
inventory of the various lifetime and current motor and
vocal tic types and a severity section, rating the number,
frequency, intensity, complexity, and interference due to
tics on a six-point Likert scale for motor and vocal tics
separately, and an overall impairment scale. The modified
YGTSS version used in TIC Genetics has left out the
number and complexity of tics as well as the assessment of
impairment, as these are not strictly needed to establish a
tic disorder diagnosis. The Y-BOCS comprises an inven-
tory of 91 types of obsessions and compulsions across
various domains followed by ratings of time spent, inter-
ference, distress, resistance, and level of control, separately
for obsessions and compulsions. All original Y-BOCS
sections are used in TIC Genetics. Finally, the reliable and
well-validated Swanson Nolan and Pelham-IV ADHD
(SNAP-IV) rating scale [43–45] is used to assess attention-
deficit/hyperactivity symptoms based on self- or parent-on-
child reports of symptoms and impairment (due to specific
ADHD symptoms) present during the primary school years
when not on medication for ADHD. The SNAP-IV is a
widely used tool for the assessment of ADHD subtypes,
scoring each nine items on inattention and hyperactivity–
impulsivity symptoms during childhood on a four-point
Likert scale ranging from ‘‘not at all’’ to ‘‘very much’’;
additional items assess age of onset and degree and per-
vasiveness of any impairment.
The questionnaires have been translated from English
into Danish, Dutch, German, Korean, and Spanish by
respective native speakers well-experienced with clinical
diagnostic instruments and were largely based on pre-
existing translations circulating in the different countries.
Additional back-translations into English were done by an
independent colleague to assure the high quality of the
translations.
The set of TIC Genetics assessments described here is
also used in other large genetic cohorts studies of TS (e.g.,
Tourette Syndrome Association International Consortium
for Genetics, TSAICG, www.findTSgenes.org, [41, 42],
TSA Genetic Linkage Consortium’s Family Self-Report
Questionnaire, January, 1995; European Multicenter Tics
in Children Studies, www.emtics.eu), thereby facilitating
future replication studies and meta-analyses.
Clinical diagnoses
As presented in Table 1, the clinical information collected
from the self-report and parent-on-child report question-
naires which are validated by clinician interview are used
to assess the lifetime and current (i.e., past week) presence
or absence of a tic disorder, OCD, trichotillomania, and
ADHD, in accordance with strict DSM-IV-TR criteria [35].
The presence or absence of sub-syndromal symptom levels
of OCD or ADHD is also rated, using the TSAICG con-
ventions [46]. The assigned diagnostic categories of tic
disorders also include provisional tic disorder based on the
DSM-5 [47] as well as a separate category not covered in
the DSM, chronic tic disorder combined subtype, for
individuals who have a verified history, with onset by age
18 years, of only a single motor tic and at least one vocal
tic. When there is diagnostic uncertainty (e.g., poor
Recruitment of 
probands and 
family members: 
multiplex families     
and parent-child 
trios
Adult self-report 
and parent-on-child 
questionnaires: 
YGTSS (tics),               
Y-BOCS (OCD),    
SNAP-IV (ADHD) 
pre/perinatal data
Clinical diagnostic 
interview and 
review of the 
questionnaires of 
all participants by 
clinician experts 
assigning clinical 
diagnoses
Single 
blood draw 
of all 
participants
Storage of 
anonymized clinical 
data and biomaterial 
in NIMH sharing 
repository: 
DNA, RNA, CPLs, LCLs
Fig. 1 Data collection procedure. YGTSS Yale Global Tic Severity
Scale, Y-BOCS Yale–Brown Obsessive–Compulsive Scale, OCD
obsessive–compulsive disorder, SNAP-IV Swanson Nolan and
Pelham-IV ADHD rating scale, ADHD attention-deficit/hyperactivity
disorder, NIMH National Institute of Mental Health, CPLs cryopre-
served lymphocytes, LCLs lymphoblastoid cell lines
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informant, uncertain historical data in an adult subject),
clinicians can opt for an ‘‘unable to rate’’ diagnosis to
reduce false negative diagnoses.
Because TIC Genetics’ priority is to acquire as large a
sample of TS probands and relatives despite the constraints
of limited funding, we have focused on the detailed
assessment of TS-related symptoms and the most common
comorbidities of OCD, ADHD, and trichotillomania. As a
result, we were not able to deploy the resources to sys-
tematically query or validate the presence of other forms of
psychopathology, either by interview or broad-based
symptom checklists. However, based on the subjects’ (or
parents’) responses on the medical history and psychotropic
medication portion of the questionnaire, clinicians queried
and reviewed with the informant any endorsed indication of
past or present treatment for conditions such as autism
spectrum disorder, anxiety or mood problems, and/or sig-
nificant neurological, medical, or genetic disorders.
When the clinician judges that there is an atypical
presentation of tic symptoms (e.g., onset after adoles-
cence, potential stereotypies rather than true tics) or the
presence of coexisting or potentially confounding psy-
chiatric and medical conditions (e.g., autism spectrum
disorder, psychosis, anxiety disorder, depression, and
neurological or genetic syndromes [7]), a corresponding
flag is entered into the database, to facilitate review. In
addition, a short diagnostic narrative is written for each
subject, briefly summarizing salient patient history and
discussing possible atypical presentations and diagnostic
uncertainties.
A Phenotype Assessment Sub-Committee, led by Drs.
King and Heiman, conducts regular case reviews, either at
random, on request, or focusing on cases flagged for
atypical presentation, confounding other conditions, or in
case of ‘‘unable to rate’’ diagnoses. In addition, the Sub-
Committee maintains a continuous dialog with the clini-
cians and provides training materials and periodic training
exercises with the goal of resolving any apparent ambi-
guities, arriving at a consensus diagnoses with the respec-
tive clinicians in ambiguous cases, ensuring consistent
application of diagnostic criteria, and helping to maintain
reliability and validity. Given the large scale of the study a
formal best estimate diagnostic consensus process by
independent expert reviewers on each subject appeared not
to be feasible.
Creation of permanent cell lines, whole-blood DNA,
and transcriptomes
Each subject donates about 30 ml of blood (four tubes) and
these are immediately shipped to the NIMH Center for
Collaborative Genomics Research on Mental Disorders at
RUCDR (RUCDR Infinite Biologics, http://www.rucdr.org)
to be processed. One tube (ACD Solution A, 8.5 ml) is
used to create cryopreserved lymphocytes (CPLs) that can
later be converted to Epstein–Barr virus-transformed per-
manent lymphoblastoid cell lines (LCLs) or induced plu-
ripotent stem cells (iPSCs). Two EDTA tubes (10 ml) are
used to extract whole-blood DNA and RNA is extracted
from one PAXgeneTM tube (2.5 ml) for future transcrip-
tomic studies.
Data management and ethical issues
All anonymized clinical and biomaterial data from all
participating centers are stored indefinitely in a central
database within the NIMH Center for Collaborative
Genomics Research on Mental Disorders at RUCDR
(RUCDR Infinite Biologics, http://www.rucdr.org). The
coded de-identified clinical diagnostic information is
entered by each center into the online encrypted and
password-protected diagnostic system via the TIC Genet-
ics website (http://tic-genetics.org). Thus, no identifying
personal information is sent from the participating sites or
received by the data coordinating center or the repository.
The subject’s identity is known only to the local research
team of the collaborating centers, where the subject’s code
(consisting of a unique site, family and subject ID number)
is kept in a secured place for a certain period of time and
subsequently anonymized in accordance with local medi-
cal-ethical regulations. The study is governed by the
National Institutes of Health’s overall Human Investiga-
tions policies and reviewed and approved by each site’s
Human Investigations Committee. The included subjects
consent to the anonymized storage of biomaterials in the
database. Finally, a publication committee regulates the
group’s access to the database and publication plans.
Sample description
Table 2 presents the current number of singleton probands,
parent–child trios, and multiplex families in the repository.
Table 3 shows the distribution of clinical diagnoses. The
ongoing TIC Genetics repository currently (as of Septem-
ber 3rd, 2013) includes a total of 988 subjects (57 % males;
91.5 % white, 1.5 % black, 7.6 % Asian, and 3.3 % of
mixed or unknown race) with available DNA and clinical
evaluations; of these 492 (49.8 %) have TS or another
chronic tic disorder. The repository consists of 274
(27.7 %) probands and 714 (72.3 %) relatives of whom
378 (52.9 %) are affected with a tic disorder and/or OCD,
and 324 (45.4 %; 32.8 % of the whole sample) are unaf-
fected with either tics or related disorders (i.e., absence of
tic disorder, OCD, subclinical OCD, OC symptoms,
trichotillomania, and ADHD).
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Genetic data analyses
Multiplex families
Whole-exome and SNP genotyping are performed on
multiplex families. Genotyping data are used to detect
CNVs using multiple algorithms [28] and to perform an
affected-only parametric linkage analysis. Linkage analysis
will be performed using Illumina Omni BeadChip geno-
type data, pruned to a subset of well-spaced SNP probes,
minimizing those in high linkage disequilibrium. Those
families yielding the highest LOD scores (logarithm [base
10] of odds) will be identified. All rare coding variants that
are plausibly disruptive (nonsense mutations including
frameshift indels, missense mutations at highly conserved
residues, and substitutions at canonical splice sites) and not
present in existing control databases will be confirmed by
Sanger sequencing and then evaluated for segregation in all
affected family members. Further studies will be consid-
ered for segregating mutations for which more than one
family shows rare segregating mutations in the same gene.
Follow-up will include sequencing of the suspect gene in
probands from every multiplex family, with further ana-
lysis of segregation in that pedigree if additional mutations
are identified.
Simplex families (parent–child trios)
The exomes of affected subjects and their unaffected par-
ents from simplex trios are sequenced using validated
protocols for capture, sequence, analysis, and annotation
[48]. For both inherited and de novo sequence variant
detection, only positions with at least 8-fold coverage will
be considered, based on 99.8 % (for inherited) and 96 %
(for de novo) confirmation of variants at this threshold [48].
All de novo variants will be confirmed by re-amplification
of native DNA and Sanger sequencing in all family
members while blinded to affected status. Inherited vari-
ants will not be routinely validated due to the extremely
high positive predictive value of such calls. The frequen-
cies of sequence variants will be determined by comparison
with the latest version of dbSNP (Single Nucleotide
Polymorphism Database) and an existing collection of
more than 2,000 unrelated whole-exome controls
sequenced at Yale for other studies. A sequence variant
will be classified as ‘‘novel’’ if it is not present in dbSNP
and not present in the control exomes, ‘‘rare’’ if not novel
and seen in\1 % of control exomes, or ‘‘common’’ if it is
present in at least 1 % of control exomes. Variants will be
mapped against the current RefSeq gene definitions (Ref-
erence Sequence database) to determine the effect of each
variant on the resulting amino acid sequence. If multiple
RefSeq gene isoforms are present, all will be manually
examined for nonsense and splice site variants, as these are
predicted to have the greatest impact on protein function. A
variant will be considered to alter the splice site only if it
disrupts the canonical two base-pair acceptor and donor
sites adjacent to 98.5 % of exons in the human genome.
These sites are among the most highly conserved base pairs
in the human genome and such splice site variants have the
potential to cause highly disruptive events, akin to non-
sense variants and frameshift indels. Furthermore, variants
will be mapped against a list of brain-expressed genes
determined by expression array analysis across 57 post-
mortem brains and multiple brain regions in a recent study
of the human brain transcriptome throughout development
and adulthood [49].
Gene-environment
The TIC Genetics study also aims to systematically
investigate the role of selected environmental determinants
of tic disorders, including prenatal (e.g., exposure to
Table 2 Number of singleton probands, parent–child trios, multiplex
families, and other families in the repository (N = 988 subjects)
Narrow
model
N
Intermediate
model
N
Broad
model
N
Singleton probandsa 26 26 26
Triosb 218 218 218
Simplex triosc 91 91 78
All Multiplex familiesd 53 62 76
Multiplex families with
3 affected
34 39 46
Multiplex families with
4 affected
12 14 20
Multiplex families with
5? affected
7 9 10
Other familiese 58 57 55
Data can be analyzed using different diagnostic models of family
members’ affectedness: Narrow (affected with Tourette syndrome or
another chronic tic disorder), Intermediate (affected with any type of
tic disorder, including transient tic disorder, provisional tic disorder,
and tic disorder-NOS), and Broad (affected with any type of tic dis-
order and/or obsessive–compulsive disorder)
a A proband is the index patient affected with Tourette syndrome or
another chronic tic disorder
b Total number of parent–child trios, i.e., affected proband and both
biological parents; these trios can be part of a multiplex family and
relatives can be affected
c Without known relatives affected with a tic disorder (or obsessive–
compulsive disorder as in the broad model; note that this has resulted
in a lower number of simplex trios)
d Mean number of subjects per multiplex family [between M = 5.3
and M = 5.7, range 3–15] and mean number affected [M = 3.7,
range 3–9, all models]
e Families with two affected persons, or ‘trios’ with a missing parent
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alcohol, smoking or drug use), perinatal (e.g., delivery
complications, birth weight and gestational age) and post-
natal factors (e.g., infections) by (1) making comparisons
between affected cases and controls by logistic regression;
(2) relate prenatal, perinatal, and postnatal factors to tic
severity and severity of comorbid conditions with linear
regression within affected individuals; (3) identify critical
time windows for the various post-natal environmental
factors (exposure9time interactions); and (4) investigating
gene9environment interactions, using a case–control
design. A candidate gene approach will be chosen for the
gene9environment studies, focusing on the replication of a
comprehensive range of previously implied genes in TS by
selection of SNPs that have been suggested in the available
literature (e.g., [23, 24, 50]). The SNP selection covers all
relevant genes in previously implicated catecholamine
pathways (including dopamine, serotonin, histamine,
GABA, and glutamate), non-neurotransmitter SNPs (e.g.,
SLITRK1, CNTNAP2), and SNPs implied by GWAS in
TS, OCD, ADHD, and autism cohorts.
Conclusion
The ongoing TIC Genetics study is an international col-
laborative effort aimed at understanding the genetic
architecture of tic and related disorders. TIC Genetics has
established an infrastructure to collect a large, well-
characterized patient cohort in the service of identifying
definitive risk genes for TS. The study’s database consists
of detailed phenotypic data on TS and other tic disorders as
well as commonly comorbid conditions (e.g., OCD,
ADHD) along with DNA, transformed cell lines, and
blood-derived RNA of affected individuals and their rela-
tives, especially family pedigrees with multiply affected
individuals and parent–child trios. The study promotes the
use of novel cutting-edge gene-finding methods. Moreover,
the collected anonymized data and biomaterial will be
stored as a permanent resource for qualified researchers in
the field of TS.
TIC Genetics study’s central mission is the creation of a
sharing repository that will contribute to advancing the
understanding of the genetics, biology, phenomenology,
and treatment of TS. The clinical and biomaterial data are
part of the NIMH Center for Collaborative Genomics
Research on Mental Disorders, USA and will be made
accessible by the NIMH within 6 months after the inclu-
sion of the last subject to qualified scientists studying the
genetics of TS and comorbid disorders. Information on
how to gain access to clinical data, DNA, and transformed
cell lines from NIMH can be found on https://www.nimh
genetics.org/access_data_biomaterial.php.
The TIC Genetics study has been designed to facilitate
cooperation with other genetic TS consortia and research-
ers, with the promise to further advance the field of
genetics of TS and related disorders. Ultimately, this may
Table 3 Frequency of clinical diagnoses per sex across probands, relatives, and the total sample (N = 988 subjects)
N
M (range) age
yrs
% sex
Tourette
syndrome
Chronic tic
disordera
Other tic
disordersb
OCD Sub-clinical OC disorder
and OC symptoms
Trichotillomania ADHDc
N (%)
m/f
N (%)
m/f
N (%)
m/f
N (%)
m/f
N (%)
m/f
N (%)
m/f
N (%)
m/f
Probandsd 274
15.9 (5–74)
77 % male
260 (94.9)
198/62
14 (5.1)
13/1
n/a 130
(47.4)
96/34
57 (20.8)
45/12
12 (4.4)
9/3
110
(36.5)
88/22
Relatives 714
40.9 (4–83)
49.3 % male
131 (18.3)
79/52
87 (12.2)
42/45
41 (5.7)
22/19
119
(16.7)
45/74
130 (18.2)
64/66
25 (3.5)
8/17
63 (8.8)
32/31
Total
sample
988
28.4 (4–83)
57 % male
391 (39.6)
277/114
101 (10.2)
55/46
41 (4.2)
22/19
249
(25.2)
141/
108
187 (18.9)
109/78
37 (3.7)
17/20
173
(17.5)
120/53
OCD obsessive–compulsive disorder, OC obsessive–compulsive, ADHD attention-deficit/hyperactivity disorder, m males, f females. Note that
due to comorbidity across the diagnostic categories counts do not add up to the total. Of the 492 subjects with Tourette syndrome or chronic tic
disorder, 23.6 % have comorbid OCD only, 14.2 % comorbid ADHD only, 16.9 % both comorbid OCD and ADHD, 3.9 % comorbid autism
spectrum disorder, 3.5 % comorbid anxiety disorder, and 6.5 % comorbid mood disorder
a Motor or vocal tic disorder, or a separate combined subtype (defined by only a single motor tic and at least one vocal tic, with onset by age
18 years)
b Transient tic disorder, provisional tic disorder, and tic disorder-NOS
c Includes combined, predominantly inattentive, and predominantly hyperactive–impulsive type
d Index patient affected with Tourette syndrome or another chronic tic disorder
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enhance our understanding of TS and further the devel-
opment of novel therapies for patients with TS to increase
their quality of life.
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